此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估Inebilizumab在儿科IgG4相关疾病参与者中的药代动力学、药效学、安全性和耐受性的研究

2026年11月10日 更新者:Amgen

一项开放标签、非对照、多中心试验,旨在评估伊奈利珠单抗在2岁至18岁以下免疫球蛋白G4相关疾病(IgG4-RD)患儿中的药代动力学、药效学、安全性和耐受性

The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD), as well as to assess the safety and tolerability, of inebilizumab in pediatric participants with IgG4-RD.

研究概览

地位

招聘中

研究类型

介入性

注册 (估计的)

15

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100730
        • 招聘中
        • Peking Union Medical College Hospital
    • Chongqing Municipality
      • Chongqing、Chongqing Municipality、中国、401122
        • 招聘中
        • Childrens Hospital of Chongqing Medical University
    • Hunan
      • Changsha、Hunan、中国、410000
        • 招聘中
        • The Second Xiangya Hospital of Central South University
      • Ankara、土耳其(türkiye)、06100
        • 招聘中
        • Hacettepe Universitesi Tip Fakultesi Hastanesi
      • Istanbul、土耳其(türkiye)、34098
        • 招聘中
        • Istanbul Universitesi Cerrahpasa Tip Fakultesi
      • Istanbul、土耳其(türkiye)、34764
        • 招聘中
        • Umraniye Egitim ve Arastirma Hastanesi
    • Ceará
      • Fortaleza、Ceará、巴西、60140-025
        • 招聘中
        • Centro Oncologia Leonardo Da Vinci
    • Estado de Bahia
      • Salvador、Estado de Bahia、巴西、40110-060
        • 招聘中
        • Universidade Federal da Bahia - Hospital Universitario Professor Edgard Santos
    • Rio Grande do Sul
      • Porto Alegre、Rio Grande do Sul、巴西、90035-903
        • 招聘中
        • Hospital de Clinicas de Porto Alegre
      • Athens、希腊、11527
        • 招聘中
        • General Children Hospital Panagioti and Aglaias Kyriakou
      • Athens、希腊、11521
        • 招聘中
        • Euroclinic Children Hospital
      • Roma、意大利、00165
        • 招聘中
        • IRCCS Ospedale Pediatrico Bambino Gesu
      • Warsaw、波兰、04-730
        • 招聘中
        • Instytut Pomnik-Centrum Zdrowia Dziecka
      • Warsaw、波兰、03-712
        • 招聘中
        • Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
      • Wroclaw、波兰、52-114
        • 招聘中
        • Szpital Specjalistyczny Im A Falkiewicza we Wroclawiu
    • Florida
      • Tampa、Florida、美国、33612
        • 招聘中
        • University of South Florida - Carol and Frank Morsani Center for Advanced Health Care
    • North Carolina
      • Chapel Hill、North Carolina、美国、27599
        • 招聘中
        • University of North Carolina at Chapel Hill
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15224
        • 招聘中
        • University of Pittsburgh Medical Center Childrens Hospital of Pittsburgh
    • Valencia
      • Valencia、Valencia、西班牙、46026
        • 招聘中
        • Hospital Universitari i Politecnic La Fe

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

2年 至 18年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  1. Participants must weigh ≥ 17 kg to be eligible for enrollment.
  2. Participant has provided informed consent/assent before initiation of any study-specific activities/procedures. Participant's legally authorized representative has provided informed consent when the participant is legally too young to provide informed consent, and the participant has provided written assent based on local regulations and/or guidelines before any study-specific activities/procedures being initiated.
  3. Age 2 to < 18 years at the time of screening. For participants who reach the age of legal consent during the clinical study, notification will be required, and a new consent form must be signed by the participant for continuation in the study.
  4. Clinical diagnosis of IgG4-RD.
  5. Fulfillment of the 2019 American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) classification criteria as determined by the principal investigator (PI) at screening. Specifically, participants must meet the classification criteria entry requirements (including involvement of one of the following organs: pancreas, bile ducts/biliary tree, orbits, lungs, kidneys, lacrimal glands, major salivary glands, retroperitoneum, aorta, pachymeninges, or thyroid gland [Riedel's thyroiditis]), must not meet any of the classification criteria exclusions, and must achieve at least 20 classification criteria inclusion points.
  6. Receipt of all age-appropriate and locally-required vaccinations before screening.
  7. Participants requiring treatment in addition to or other than glucocorticoids (GCs) for IgG4-RD according to PI's assessment at screening.
  8. Participants who are on GCs for the treatment of IgG4-RD should remain on a stable dose for at least 2 weeks before enrollment (Day 1). Tapering post enrollment will be at PI's discretion.

Key Exclusion Criteria:

  1. Participants with any of the following abnormal liver function tests in the presence of hepatobiliary IgG4-RD activity:

    • aspartate aminotransferase (AST) > 10 × upper limit of normal (ULN)
    • alanine aminotransferase (ALT) > 10 × ULN
    • total bilirubin (TBL) > 5 × ULN Screening liver function tests may be repeated before Day 1 to permit abnormal values due to hepatobiliary IgG4-RD activity to respond to GC treatment.
  2. Evidence of significant hepatic, renal, or metabolic dysfunction or significant hematological abnormality, including any of the following at screening (one repeat test may be conducted to confirm results within the same screening period):

    • platelet count < 75000/μL (or < 75 × 109/L)
    • absolute neutrophil count < 1200 cells/μL
    • total Ig < 600 mg/dL
    • CD4 T lymphocyte count < 300 cells/µL
    • hemoglobin < 8 g/dL (or < 80 g/L).
  3. Estimated glomerular filtration rate < 45 mL/min/1.73 m^2.

  4. B-cell counts < one-half of the lower limit of normal (LLN) for age according to the central laboratory.

  5. Diagnosed with a concurrent autoimmune disease that is uncontrolled or requires any prohibited medication (unless approved by the medical monitor).

  6. Clinically significant serious active or chronic viral, bacterial, or fungal infection that requires treatment with anti-infectives, hospitalization, or, in the investigator's opinion, represents an additional risk to the participant, within 2 months before Day 1 of study.

  7. Known history of congenital or acquired immunodeficiency (eg, due to human immunodeficiency virus [HIV] infection, splenectomy, immunosuppression-related or idiopathic T-cell deficiencies) that predisposes the participant to infection.

  8. Positive test for chronic hepatitis B infection at screening, defined as either: (1) Positive hepatitis B surface antigen (HBsAg); or (2) Positive hepatitis B core antibody (anti-HBc) PLUS negative hepatitis B surface antibody (anti-HBs). Note: Participants with a positive anti-HBs only, or a positive anti-HBc plus positive anti-HBs and negative HBsAg, are eligible to enroll.

  9. Receipt of any of the following before Day 1: alemtuzumab, total lymphoid irradiation, bone marrow transplant, T-cell vaccination therapy.

  10. Receipt of any of the following within 2 months before Day 1: azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, cyclophosphamide, tocilizumab, satralizumab, eculizumab, and mitoxantrone.

  11. Receipt of rituximab or any experimental B-cell depleting agent (eg, ocrelizumab, obinutuzumab, ofatumumab, inebilizumab), or any non-depleting B-cell-directed therapy (eg, belimumab), abatacept, within 6 months before screening unless B-cell counts have returned to ≥ one-half the LLN.

  12. Receipt of any live or attenuated vaccine (administration of inactivated [killed] vaccine is acceptable) within 4 weeks before Day 1, Bacillus Calmette-Guérin vaccine within 1 year of screening, or blood transfusion within 4 weeks before screening or during screening.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Inebilizumab

Participants will receive Inebilizumab via intravenous (IV) infusion.

Inebilizumab will be administered via IV infusion.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
伊奈利珠单抗的最大血浆浓度(Cmax)
大体时间:最长至第561天
最长至第561天
伊奈利珠单抗血浆浓度-时间曲线下面积 (AUC)
大体时间:最长至第561天
最长至第561天
伊奈利珠单抗清除率 (CL)
大体时间:最长至第561天
最长至第561天
伊奈利珠单抗的终末半衰期(t½)
大体时间:最长至第561天
最长至第561天
伊奈利珠单抗稳态分布容积(Vss)
大体时间:最长至第561天
最长至第561天
基线CD20+B细胞计数变化
大体时间:基线和第561天
基线和第561天
发生不良事件(AEs)的受试者人数
大体时间:截至第561天
截至第561天
发生严重不良事件(SAE)的受试者人数
大体时间:基线至第561天
基线至第561天
发生关注事件(EOI)的受试者数量
大体时间:基线至第561天
基线至第561天
出现实验室参数较基线发生临床显著变化的受试者人数
大体时间:基线至第561天
基线至第561天
出现生命体征较基线发生临床显著变化的受试者人数
大体时间:基线至第561天
基线至第561天

次要结果测量

结果测量
大体时间
52周内首次治疗性发作时间
大体时间:最长至第52周
最长至第52周
52周内无发作参与者的百分比
大体时间:至第52周
至第52周
52周内年化发作率
大体时间:直至第52周
直至第52周
治疗开始前后抗药物抗体(ADA)的存在情况
大体时间:第1天至第561天
第1天至第561天
第52周时每日糖皮质激素剂量较基线的百分比下降
大体时间:基线和第52周
基线和第52周

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:MD、Amgen

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年10月21日

初级完成 (估计的)

2031年6月10日

研究完成 (估计的)

2031年6月10日

研究注册日期

首次提交

2025年10月28日

首先提交符合 QC 标准的

2025年10月28日

首次发布 (实际的)

2025年10月30日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 20240202
  • 2025-520988-41-00 (克蒂斯)
  • 2025 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

IPD 共享时间框架

Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

IPD 共享访问标准

Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅